High Tech Pharm. Co., Ltd.

As of March 31, 2026, High Tech Pharm. Co., Ltd. carries a market capitalization of 230.73B, placing it among publicly traded companies globally. Its enterprise value stands at 222.28B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, High Tech Pharm. Co., Ltd. has 10.63M shares outstanding.

As of March 31, 2026, High Tech Pharm. Co., Ltd. trades at a trailing price-to-earnings ratio of 25.57. The price-to-sales ratio is 3.34, and the price-to-book ratio stands at 1.79.

As of March 31, 2026, High Tech Pharm. Co., Ltd. trades at an EV/EBITDA multiple of 15.14 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.22 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 24.17 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. High Tech Pharm. Co., Ltd. trades at an EV/FCF ratio of 105.59, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 222.28B versus a market cap of 230.73B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, High Tech Pharm. Co., Ltd. maintains a current ratio of 4.62, meaning it holds 4.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.02, indicating conservative leverage, while an interest coverage ratio of 162.89 demonstrates strong ability to service its debt obligations.

Over the twelve months ended March 31, 2026, High Tech Pharm. Co., Ltd. posted a return on equity (ROE) of 7.23, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 5.90 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.30, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 7.06, useful for judging operating efficiency across full business cycles. The company generates approximately 541.57M in revenue per employee across its workforce of 127.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.27 indicates how many times High Tech Pharm. Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, High Tech Pharm. Co., Ltd. recorded 1.85B in income tax expense. That works out to an effective tax rate of 17.01, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 10.87B, leaving 9.02B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, High Tech Pharm. Co., Ltd.'s stock has declined approximately 31.43% over the past 52 weeks. The 50-day moving average sits at 10,500.20, while the 200-day moving average is 13,723.05.

Over the twelve months ended March 31, 2026, High Tech Pharm. Co., Ltd. generated 69.05B in revenue and converted that into 9.02B in net income, yielding earnings per share of 844.67. EBITDA reached 14.68B, while operating income came in at 9.20B.

As of March 31, 2026, High Tech Pharm. Co., Ltd. holds 8.47B in cash and equivalents against 27.13M in total debt, resulting in a net debt position of -7.98B. Total book value stands at 128.81B, with working capital of 57.99B providing operational flexibility.

High Tech Pharm. Co., Ltd. produced 3.88B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -1.85B in capital expenditures, free cash flow totaled 2.03B - equivalent to 190.95 per share.

Over the twelve months ended March 31, 2026, High Tech Pharm. Co., Ltd. posted a gross margin of 23.05, reflecting its pricing power and cost economics. The operating margin of 13.32 and net profit margin of 13.07 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, High Tech Pharm. Co., Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 0.88, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.91, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to High Tech Pharm. Co., Ltd. shareholders.

High Tech Pharm. Co., Ltd.'s most recent stock split took place on December 27, 2023 with a 2:3 split ratio.

As of March 31, 2026, High Tech Pharm. Co., Ltd. has an Altman Z-Score of 10.50, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.